Unit 6: Research ethics - Subjective Questions

An Institutional Review Board (IRB), also called an Ethics Committee or Institutional Ethics Committee (IEC), is a formally designated group established to review, approve, and monitor biomedical and behavioral research involving human subjects. Its central mandate is to protect the rights, safety, and welfare of research participants.

Primary functions:

• Protocol review: Examines research proposals before initiation to ensure ethical soundness.
• Risk–benefit assessment: Confirms that potential benefits justify the risks to participants.
• Informed consent oversight: Ensures the consent process and documents are adequate, understandable, and voluntary.
• Protection of vulnerable groups: Applies additional safeguards for children, prisoners, pregnant women, and cognitively impaired persons.
• Continuing review: Monitors ongoing studies at intervals (at least annually) and reviews amendments.
• Adverse event monitoring: Reviews reports of harm and can suspend or terminate studies.
• Compliance: Ensures research conforms to national regulations and international guidelines (e.g., Declaration of Helsinki, ICH-GCP).

In short, the IRB serves as an independent ethical gatekeeper that balances scientific advancement with human protection.

Clinical research involves testing interventions on human subjects, which raises several ethical challenges:

• Informed consent: Participants must understand the purpose, procedures, risks, and their right to withdraw. Addressed through clear, voluntary, documented consent.
• Risk–benefit balance: Risks must be minimized and reasonable relative to anticipated benefits.
• Placebo use: Using placebos when effective treatment exists is ethically contentious; addressed by using active comparators where appropriate.
• Confidentiality and privacy: Protection of participant data through anonymization and secure storage.
• Conflicts of interest: Financial or professional interests may bias research; managed by disclosure and independent oversight.
• Exploitation of vulnerable populations: Requires additional protections.
• Fair subject selection: Burdens and benefits of research should be distributed justly.
• Post-trial access: Ensuring participants can access beneficial treatments after the trial.

Frameworks addressing these: The Belmont Report principles (respect for persons, beneficence, justice), the Declaration of Helsinki, and Good Clinical Practice (GCP) guidelines, all enforced through IRB oversight.

Vulnerable populations are groups of individuals who have a limited capacity to protect their own interests or may be susceptible to coercion or undue influence when participating in research.

Examples include:

• Children and minors — lack legal capacity to consent.
• Pregnant women and fetuses — potential harm to the unborn.
• Prisoners — freedom may be compromised; risk of coercion.
• Cognitively or mentally impaired individuals — diminished decision-making ability.
• Economically or educationally disadvantaged persons — may be swayed by incentives.
• Terminally ill patients — desperation may impair judgment.
• Ethnic minorities and marginalized groups.

Special protections required:

• Additional IRB scrutiny and justification for including them.
• Surrogate/proxy consent with the participant's assent where possible.
• Minimizing risk to the lowest level.
• Avoiding excessive inducements that could constitute coercion.
• Ensuring the research directly benefits the group or cannot be done in a less vulnerable population.
• Independent advocates to safeguard interests.

These protections uphold the principle of respect for persons and justice.

A risk–benefit analysis is the systematic evaluation of the potential harms against the potential benefits of a research study. It is a core ethical requirement rooted in the principle of beneficence (maximize benefit, minimize harm).

Types of risks:

• Physical (pain, injury, side effects)
• Psychological (stress, anxiety)
• Social (stigma, discrimination)
• Economic (loss of employment, costs)
• Legal (breach of confidentiality)

Types of benefits:

• Direct benefits to participants (improved treatment).
• Societal benefits (generalizable knowledge, advances in science).

Key principles of the analysis:

• Risks must be minimized through sound study design.
• Risks must be reasonable in relation to anticipated benefits.
• Benefits should not be overstated, and monetary compensation is not counted as a benefit.
• Vulnerable groups require an even more favorable ratio.

The IRB uses this analysis to decide whether a study is ethically justifiable to proceed.

Authorship confers credit and accountability for a scientific work. Ethical issues arise from improper attribution of authorship.

Criteria for authorship (ICMJE): An author should meet all of the following —

• Substantial contribution to conception, design, data acquisition, or analysis.
• Drafting or critically revising the manuscript.
• Final approval of the version to be published.
• Accountability for the work's integrity.

Common ethical problems:

• Ghost authorship: A person who contributed significantly (often a writer) is omitted.
• Gift/honorary authorship: Including someone (e.g., a senior head) who did not contribute.
• Guest authorship: Adding a prominent name to increase credibility.
• Order disputes: Conflict over the sequence of author names.
• Denial of due credit to junior researchers or students.

Consequences: Misrepresentation of contributions undermines research integrity, accountability, and fairness.

Best practices: Establish authorship agreements early, follow standard guidelines, and acknowledge non-author contributors appropriately.

Human protectionism (protection of human subjects) refers to the collection of ethical principles, regulations, and practices aimed at safeguarding the rights, dignity, welfare, and safety of humans who participate in research.

Guiding principles (Belmont Report):

• Respect for persons: Individuals are autonomous agents; those with reduced autonomy deserve protection. Realized through informed consent.
• Beneficence: Do no harm; maximize benefits and minimize risks.
• Justice: Fair distribution of the burdens and benefits of research; no exploitation of vulnerable groups.

Mechanisms of protection:

• Informed consent processes.
• IRB/Ethics committee review.
• Confidentiality and data protection.
• Right to withdraw without penalty.
• Special safeguards for vulnerable populations.
• Regulatory frameworks (Nuremberg Code, Declaration of Helsinki, GCP).

Human protectionism emerged historically in response to abuses such as the Nazi experiments and the Tuskegee syphilis study, ensuring that scientific progress never comes at the cost of human dignity.

Research ethics governs the responsible conduct of research. Common issues include:

• Scientific misconduct:
  • Fabrication — inventing data.
  • Falsification — manipulating data or results.
  • Plagiarism — using others' work without credit.
• Informed consent violations.
• Conflicts of interest: Financial or personal biases.
• Data management issues: Improper storage, selective reporting, data dredging.
• Authorship disputes: Ghost, gift, and guest authorship.
• Duplicate/redundant publication and salami slicing.
• Confidentiality breaches.
• Animal welfare concerns in preclinical work.
• Exploitation of vulnerable populations.
• Publication bias: Suppressing negative results.
• Peer-review misconduct.

Addressing these issues requires adherence to codes of conduct, institutional oversight, training in Responsible Conduct of Research (RCR), transparency, and accountability at every stage of the research lifecycle.

Human cloning is the creation of a genetically identical copy of a human. It raises profound ethical concerns and is generally categorized into two types.

1. Reproductive cloning — producing a cloned human being:

• Safety: High rates of failure, deformities, and abnormalities (as seen in animal cloning).
• Human dignity: Treats a person as a manufactured product.
• Identity and individuality: Concerns over the psychological welfare of the clone.
• Family and social relationships: Confusion of kinship and parentage.
• Eugenics: Potential for 'designer' selection.

Most countries ban reproductive cloning.

2. Therapeutic cloning — creating embryos to derive stem cells for treatment:

• Moral status of the embryo: Destroying embryos raises 'right to life' debates.
• Instrumentalization of human life.
• Commodification and exploitation of egg donors.
• Slippery slope toward reproductive cloning.

Ethical principles involved: respect for human dignity, beneficence, non-maleficence, and justice. The debate balances potential medical benefits against the moral status of the human embryo.

Stem cell research holds promise for treating many diseases but is ethically debated, particularly regarding embryonic stem cells.

Sources of stem cells:

• Embryonic stem cells (ESCs) — derived from embryos; pluripotent but ethically contentious.
• Adult (somatic) stem cells — fewer ethical concerns.
• Induced pluripotent stem cells (iPSCs) — reprogrammed adult cells; avoid embryo destruction.

Key ethical issues:

• Moral status of the embryo: Deriving ESCs destroys the embryo, raising the question of when human life and personhood begin.
• Consent for embryo/tissue donation: Donors must give informed consent; concerns over IVF surplus embryos.
• Commodification of human tissue: Buying/selling of embryos or eggs.
• Exploitation of egg donors: Health risks from ovarian stimulation.
• Justice and access: Who benefits from expensive therapies.
• Safety: Risk of tumor (teratoma) formation and immune rejection.

Resolution efforts: Development of iPSCs and adult stem cells reduces ethical objections, while regulatory oversight ensures responsible research.

Biological weapons use pathogens or toxins (bacteria, viruses, fungi) to cause disease, death, or incapacitation in humans, animals, or plants. Their development and use raise grave social and ethical concerns.

Ethical implications:

• Violation of the principle of non-maleficence: Deliberate causing of mass harm.
• Indiscriminate harm: Affect combatants and innocent civilians alike.
• Dual-use dilemma: Legitimate biomedical research can be misused for weapons.
• Betrayal of scientific ethics: Perverts science meant to heal into a tool of destruction.
• Uncontrollable consequences: Pathogens can spread beyond intended targets, causing pandemics.

Social implications:

• Fear and terror among populations.
• Public health burden and healthcare collapse.
• Economic disruption and long-term ecological damage.
• Erosion of trust in scientific institutions.

Regulatory response: The Biological Weapons Convention (BWC, 1972) prohibits development, production, and stockpiling of biological weapons. Ethical responsibility requires scientists to practice biosecurity, oversight of dual-use research, and adherence to international law.

Euthanasia is the act of intentionally ending a person's life to relieve suffering, typically in the context of incurable or terminal illness. The term derives from Greek meaning 'good death.'

Classification based on consent:

• Voluntary euthanasia: Performed with the patient's explicit consent.
• Non-voluntary euthanasia: Patient is unable to consent (e.g., comatose); decision made by others.
• Involuntary euthanasia: Carried out against the patient's will (widely condemned, akin to murder).

Classification based on the method of action:

• Active euthanasia: Deliberate action to cause death (e.g., lethal injection).
• Passive euthanasia: Withholding or withdrawing life-sustaining treatment, allowing natural death.

Related concept:

• Physician-assisted suicide (PAS): The physician provides the means, but the patient performs the final act.

Ethical debate centers on autonomy (right to choose) versus the sanctity of life and the risk of abuse. Legal status varies widely across countries.

Both forms of euthanasia aim to end suffering but differ in method and moral treatment.

Ethical considerations:

• Autonomy: Both may respect patient wishes.
• The killing vs. letting die distinction: Many argue active euthanasia is morally worse because of direct intent, while others argue the outcome (death) is the same, making the distinction morally irrelevant.
• Beneficence and non-maleficence: Relief of suffering vs. duty not to kill.
• Slippery slope concern: Active euthanasia raises fears of abuse.

In many jurisdictions (including India, via the Aruna Shanbaug and Common Cause judgments), passive euthanasia is permitted under strict safeguards, whereas active euthanasia remains prohibited.

Composition of an IRB:

To ensure balanced and competent review, an IRB typically includes:

• Scientific members — experts in the relevant research field (e.g., clinicians, biologists).
• Non-scientific members — such as ethicists, lawyers, or social scientists.
• A layperson — representing community/patient interests.
• Members independent of the institution to avoid conflict of interest.
• Diversity in gender, background, and expertise.
• Usually a minimum of five members, with a designated chairperson.

Review process:

1. Submission: Researcher submits the protocol, consent forms, and supporting documents.
2. Categorization of review:
   • Exempt review — minimal-risk studies.
   • Expedited review — low-risk studies reviewed by a subset.
   • Full board review — greater-than-minimal-risk studies reviewed by the entire committee.
3. Evaluation: Assessment of scientific validity, risk–benefit ratio, consent adequacy, and participant protection.
4. Decision: Approval, approval with modifications, deferral, or rejection.
5. Continuing review: Periodic monitoring, amendment review, and adverse event tracking.

This process guarantees independent, ethical oversight of research involving humans.

Informed consent is a voluntary agreement by a competent individual to participate in research after being fully informed about it. It is the practical realization of the principle of respect for persons.

Essential elements:

• Disclosure: Full information about the study's purpose, procedures, duration, risks, benefits, and alternatives.
• Comprehension: Information presented in understandable language suited to the participant's level.
• Voluntariness: Free from coercion, undue influence, or excessive inducement.
• Competence: The participant must have the mental capacity to decide.
• Consent/authorization: Documented agreement, usually via a signed form.

Additional requirements:

• Right to withdraw at any time without penalty.
• Assurance of confidentiality.
• Contact information for questions.
• Assent from minors plus parental/guardian consent.
• Proxy consent for those unable to consent.

Importance: Informed consent protects autonomy, promotes trust, and is a legal and ethical prerequisite mandated by the Nuremberg Code, Declaration of Helsinki, and GCP.

Euthanasia is one of the most debated bioethical issues, with strong arguments on both sides.

Arguments in favor (pro-euthanasia):

• Autonomy: Individuals have the right to decide about their own life and death.
• Relief of suffering: Ends unbearable pain in terminal illness.
• Dignity: Allows death with dignity rather than prolonged deterioration.
• Quality over quantity of life.
• Resource allocation: Reduces prolonged, futile medical costs.
• Compassion: A merciful response to hopeless suffering.

Arguments against (anti-euthanasia):

• Sanctity of life: Life is intrinsically valuable and inviolable (religious and moral views).
• Slippery slope: May lead to abuse, involuntary euthanasia, or devaluation of vulnerable lives.
• Medical ethics violation: Conflicts with the physician's duty to 'do no harm.'
• Potential for misdiagnosis or wrong prognosis.
• Palliative care alternative: Modern pain management can relieve suffering.
• Risk of coercion: Patients may feel pressured to choose death to avoid burdening others.

Conclusion: The debate balances individual autonomy and compassion against the sanctity of life and societal safeguards, requiring careful legal and ethical regulation.

Both documents are foundational to the ethical conduct of research involving human subjects.

Nuremberg Code (1947):

• Formulated after the Nuremberg trials exposing Nazi human experimentation atrocities.
• The first international code for ethics in human experimentation.
• Key principles:
  • Voluntary informed consent is absolutely essential.
  • Research must yield beneficial results unobtainable otherwise.
  • Avoidance of unnecessary suffering and injury.
  • Right to withdraw at any time.
  • Risks should never exceed benefits.
  • Conducted by qualified persons.

Declaration of Helsinki (1964, revised several times):

• Developed by the World Medical Association (WMA).
• Expands on the Nuremberg Code specifically for medical research.
• Key contributions:
  • Distinguishes therapeutic and non-therapeutic research.
  • Requires ethics committee (IRB) review.
  • Emphasizes risk–benefit assessment and vulnerable population protection.
  • Addresses use of placebos and post-trial access.

Significance: Together they established the ethical cornerstones — informed consent, independent review, and protection of participants — that guide modern research ethics worldwide.

These three, collectively abbreviated as FFP, are the most serious forms of research misconduct that violate research integrity.

1. Fabrication:

• Definition: Making up data or results that do not exist.
• Example: Reporting experimental readings for tests never performed.

2. Falsification:

• Definition: Manipulating research materials, equipment, or processes, or changing/omitting data so results are not accurately represented.
• Example: Altering images, deleting outliers to fit a hypothesis, or misrepresenting methods.

3. Plagiarism:

• Definition: Appropriating another person's ideas, results, words, or work without giving appropriate credit.
• Example: Copying text or ideas from another paper without citation; self-plagiarism.

Consequences: All three undermine the scientific record, erode public trust, and can result in retraction of papers, loss of funding, and career termination. They are addressed through RCR training, oversight, and institutional misconduct policies.

The Belmont Report (1979) was created by the U.S. National Commission to establish ethical principles for research involving human subjects. It defines three core principles, each with a corresponding application.

1. Respect for Persons:

• Principle: Individuals are autonomous agents; persons with diminished autonomy deserve protection.
• Application → Informed Consent: Voluntary participation with full disclosure and comprehension.

2. Beneficence:

• Principle: Do no harm; maximize possible benefits and minimize possible harms.
• Application → Risk–Benefit Assessment: Systematic evaluation ensuring risks are justified by benefits.

3. Justice:

• Principle: Fairness in the distribution of research burdens and benefits.
• Application → Fair Selection of Subjects: Equitable recruitment; vulnerable groups not exploited nor unfairly excluded.

Significance:

• Provides the ethical foundation for modern research regulations.
• Guides IRB decision-making.
• Emerged in response to abuses like the Tuskegee syphilis study.

These principles collectively ensure that research is conducted with integrity, respect, and fairness toward all participants.

A conflict of interest (COI) occurs when a researcher's personal, financial, or professional interests could inappropriately influence, or appear to influence, their professional judgment and the integrity of research.

Types of conflicts:

• Financial COI: Funding from companies, stock ownership, patents, consulting fees.
• Personal COI: Relationships, friendships, or rivalries.
• Professional/academic COI: Desire for recognition, promotion, or publication.
• Institutional COI: The institution itself has a financial stake in outcomes.

Risks posed:

• Bias in study design, data interpretation, or reporting.
• Loss of objectivity and public trust.
• Compromised participant safety.

Management strategies:

• Disclosure: Declaring all potential conflicts to the IRB, journals, and institutions.
• Recusal: Removing conflicted individuals from decisions.
• Independent oversight: Third-party monitoring of data.
• Prohibition: Banning certain arrangements.
• Transparency in publication: Reporting funding sources.

Proper management preserves research integrity, objectivity, and public confidence in scientific findings.

The dual-use dilemma refers to research or technology that is conducted for legitimate, beneficial purposes but has the potential to be misused to cause harm, such as the creation of biological weapons.

Definition: Dual-Use Research of Concern (DURC) is life sciences research that, based on current understanding, could be directly misapplied to pose a significant threat to public health, safety, agriculture, or the environment.

Examples:

• Gain-of-function research making pathogens more transmissible or lethal.
• Publishing the genome sequences or synthesis methods of dangerous viruses.
• Techniques enhancing antibiotic resistance.

Ethical implications:

• Beneficence vs. non-maleficence: Balancing scientific/medical benefit against potential for catastrophic misuse.
• Scientific freedom vs. security: Open publication advances science but could aid bioterrorists.
• Responsibility of scientists: Duty to anticipate and prevent misuse.
• Transparency vs. censorship: Whether to restrict or redact sensitive findings.

Management approaches:

• Risk assessment and oversight by biosafety/biosecurity committees.
• Responsible publication policies.
• Education in responsible conduct.
• Compliance with the Biological Weapons Convention.

The dilemma demands that scientists weigh the advancement of knowledge against the obligation to protect society from harm.